BACKGROUND
Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder associated with altered bowel habits and abdominal pain or discomfort in the absence of organic disease.
Subtypes include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), and unclassifi ed IBS (IBS-U).
1 Although symptoms vary among subtypes and patients, most efforts in the management of IBS are directed at symptom control and have included dietary modifi cation, physical activity, and adjunctive pharmacological therapy, which is typically reserved for patients with moderate to severe symptoms that impair quality of life. Use of antibiotics, including rifaximin, is not routinely recommended in the management of IBS and is typically reserved for patients with moderate to severe IBS without constipation who have failed to respond to other therapies. Recommendations for antibiotic use are based on the proposed relationship between small intestine microbial overgrowth and malabsorption or excessive gas production.
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PATIENT POPULATION
Adults with signs and symptoms of IBS.
DOSAGE AND DURATION
550 mg 3 times daily for 2 weeks.
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RESULTS
Rifaximin for the management of IBS has been studied in several placebo-controlled trials (enrolling more than 1,500 treated patients) demonstrating modest effect on global IBS symptoms and benefi t in bloating in IBS patients without constipation. 5, 6 Most trials included a short-term follow-up (less than 3 months) after therapy completion. An American College of Gastroenterology (ACG) monograph on the management of IBS provides a weak recommendation for rifaximin use, based on moderate evidence indicating modest but consistent effi cacy in IBS without constipation.
Position Statement
An ACG monograph on the management of IBS and chronic idiopathic constipation states that therapies supported by high levels of evidence for improvement of IBS symptoms include linaclotide for IBS-C and antidepressants for IBS. Therapies supported by moderate levels of evidence include lubiprostone for IBS-C; alosetron in women with IBS-D; peppermint oil, psyllium, and fi ber for overall symptom relief in IBS; and rifaximin for total IBS symptoms and bloating in IBS-D. Therapies supported by low levels of evidence include probiotics for global symptoms, bloating, and fl atulence and certain antispasmodics for short-term relief of symptoms. Specialized diets are supported by This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specifi c drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specifi c use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu. very low levels of evidence. According to the statement, there is insuffi cient evidence to recommend prebiotics, synbiotics, loperamide, mixed 5-HT 4 agonists/5-HT 3 antagonists, or polyethylene glycol.
Although moderate evidence supports rifaximin for IBS, the recommendation for its use is classifi ed as weak, based on results from 5 trials in 1,805 IBS patients. Rifaximin has demonstrated modest but consistent effi cacy in the management of IBS without constipation. The monograph notes that there was a statistically signifi cant benefi t in favor of rifaximin (relative risk [RR], 0.84; 95% CI, 0.78 to 0.9), with a number needed to treat (NNT) of 9 (95% CI, 6 to 12.5). There was no difference between antibiotic therapy and placebo for risk of adverse events (RR, 0.7; 95% CI, 0.42 to 1.16).
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Controlled Trials
In 2 identically designed, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2) in 1,258 adult patients with IBS without constipation, patients were randomized to receive rifaximin (550 mg 3 times daily) or placebo for 2 weeks and were monitored for an additional 10-week period after therapy completion. The primary outcome was the percentage of patients achieving adequate relief of global IBS symptoms, as measured by patient response, for at least 2 of the fi rst 4 weeks after treatment. The secondary outcome was patient-reported relief of IBS-related symptoms, including bloating and abdominal pain and discomfort, according to a 7-point scale. Combined results from both studies revealed that signifi cantly more patients receiving rifaximin reported relief of global IBS symptoms compared with patients receiving placebo (40.7% vs 31.7%; P < .001). Similar results were also reported for IBS-related bloating (40.2% vs 30.3%; P < .001) and abdominal pain and discomfort (44.3% vs 36.3% in TARGET 1 [P = .03]; 42.9% vs 34.4% in TARGET 2 [P = .02]). Continued relief of symptoms was maintained in the rifaximin group during all 3 months in both studies. 5 
Noncontrolled Trial
A retrospective review of patients with IBS without constipation who had previously received at least 1 course of rifaximin treatment was conducted to identify the number of rifaximin retreatments, the success of additional rifaximin treatments, and the duration of benefi t with retreatment. Of 522 patient charts reviewed, 187 subjects had IBS without constipation; of these subjects, 169 had received rifaximin and 148 were evaluated at follow-up visits. Rifaximin produced clinical improvement in most patients (n = 111; 75%). Seventy-one patients experienced symptomatic relapse with documented rifaximin retreatment; the majority of this group was female (n = 44), with a mean age of 47 years. Forty-eight patients received retreatment with a second course of rifaximin, 22 received a third course, 9 received a fourth course, and 4 received a fi fth course. More than 75% of patients who initially responded to rifaximin experienced clinical benefi t with additional treatment. Although relapse rates varied for all retreatments, median duration of benefi t was at least 4 months. The authors concluded that in general, patients who respond to 1 rifaximin treatment course also respond to subsequent courses. 
Meta-analysis
A meta-analysis evaluated 5 double-blind, randomized, placebo-controlled trials (N = 1,803) that compared the effi cacy of rifaximin versus placebo for the management of IBS, as defi ned by accepted symptom criteria. The primary outcome was global improvement of IBS symptoms. Rifaximin was associated with improvement of global symptoms compared with placebo (summary odds ratio [OR], 1.57; 95% CI, 1.22 to 2.01; P < .001). Signifi cantly more patients in the rifaximin group reported global improvement in symptoms compared with placebo (42.2% vs 32.4%), with an NNT of 10.2 for therapeutic gain (9.8%). Mild heterogeneity was identifi ed (I 2 = 26%; P = .25). When patient and study characteristics were evaluated to determine impact on response rates, age was considered a signifi cant predictor of symptom improvement (OR, 1.16; 95% CI, 1.07 to 1.25). Secondary outcomes included bloating, abdominal pain, and stool consistency. Rifaximin was associated with improvement in bloating compared with placebo (OR, 1.55; 95% CI, 1.23 to 1.96; P < .001). Therapeutic gain was 9.9%, with an NNT of 10.1. Raw data regarding abdominal pain were not available, and data addressing stool consistency were confl icting in the 3 studies for which data were available. The authors concluded that rifaximin is more effective than placebo for relief of global symptoms and bloating in IBS and that therapeutic gain is similar to that demonstrated by other currently available IBS therapies.
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SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
Off-Label Drug Uses
In large placebo-controlled trials, rates of serious adverse events were similar for rifaximin and placebo (1.6% vs 2.4%, respectively). 5 In a meta-analysis, adverse events were available for 4 of the 5 studies that met inclusion criteria. Overall, the incidence of adverse events and discontinuation rates due to adverse events were similar between the placebo and rifaximin groups. The most frequently cited adverse events (up to 6%) included headache, upper respiratory tract infection, nausea, nasopharyngitis, diarrhea, and abdominal pain. 6 A pooled analysis of study data from 3 dou bleblind, placebo-controlled trials enrolling 1,940 patients evaluated the safety and tolerability of rifaximin for treatment of IBS without constipation. Mean age of patients was 46 years, and the majority (73%) was female. Most rifaximin dosage regimens were administered for 2 weeks and included 275 mg, 550 mg, or 1,100 mg twice daily, or 550 mg 3 times daily; 1 study included 550 mg twice daily for 4 weeks. The overall safety profi le indicated that the majority of adverse events were mild to moderate in nature, with a similar overall incidence rate between rifaximin and placebo (12.1% vs 10.7%). Most reactions included GI-associated complaints or infection. 8 No cases of Clostridium diffi cile-associated diarrhea or death have been reported in reviewed trials or meta-analyses. 5, 6, 8 Concerns have been raised regarding long-term or repeated use of antibiotics, including rifaximin, suggesting the drug should be limited to single, acute, short-term treatment. 9 
THERAPY CONSIDERATIONS
Rifaximin for the management of IBS has been studied in several placebo-controlled trials demonstrating modest effects on global IBS symptoms and benefi t in bloating in IBS patients without constipation. Most trials included a short-term follow-up (less than 3 months) after therapy completion. An ACG monograph on the management of IBS provides a weak recommendation for rifaximin use, based on moderate evidence indicating modest but consistent effi cacy in IBS without constipation.
